AnaptysBio Inc Stock
Price
Target price
€37.40
€37.40
-3.110%
-1.2
-3.110%
€46.41
08.01.26 / Frankfurt
WKN: A2AJ8C / Symbol: ANAB / Name: AnaptysBio / Stock / Biotechnology & Medical Research / Small Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
AnaptysBio Inc Stock
Heavy losses for AnaptysBio Inc today as the stock fell by -€1.200 (-3.110%).
With 23 Buy predictions and not a single Sell prediction AnaptysBio Inc is an absolute favorite of our community.
As a result the target price of 46 € shows a positive potential of 22.99% compared to the current price of 37.4 € for AnaptysBio Inc.
Criterium "Worthwhile Investment for the next years" is seen as the biggest plus for AnaptysBio Inc stock. Negative votes have not been in the majority for any criteria for this stock
Pros and Cons of AnaptysBio Inc in the next few years
Pros
?
B****
?
C******** o* t** e**********
?
G***** c******* t* c**********
Cons
?
M***** P*******
?
S********** s********
?
W********* I********* f** t** n*** y****
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of AnaptysBio Inc vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| AnaptysBio Inc | -3.110% | -1.579% | -0.532% | 171.014% | -13.023% | 83.333% | 82.528% |
| NanoViricides Inc. | 0.990% | 0.000% | -9.735% | -22.727% | 9.677% | -17.542% | -61.654% |
| Actinium Pharmaceuticals Inc. | 2.860% | 2.852% | -2.936% | -7.321% | -1.408% | -86.408% | -82.370% |
| Immunic Inc. | 1.750% | 15.261% | -0.520% | -44.648% | 33.488% | -55.846% | -96.068% |
Comments
AnaptysBio (NASDAQ:ANAB) had its "buy" rating reaffirmed by analysts at Guggenheim.
Show more
Ratings data for ANAB provided by MarketBeat
AnaptysBio (NASDAQ:ANAB) had its price target lowered by analysts at Stifel Nicolaus from $80.00 to $56.00. They now have a "buy" rating on the stock.
Show more
Ratings data for ANAB provided by MarketBeat
AnaptysBio (NASDAQ:ANAB) had its price target lowered by analysts at HC Wainwright from $52.00 to $51.00. They now have a "buy" rating on the stock.
Show more
Ratings data for ANAB provided by MarketBeat
News
AnaptysBio (ANAB) Q2 Revenue Jumps 103%
AnaptysBio (NASDAQ:ANAB), a clinical-stage biotechnology company focused on innovative immunology therapeutics for autoimmune and inflammatory diseases, released its Q2 2025 earnings on August 6
